$2.78
3.35% day before yesterday
Nasdaq, Dec 27, 10:11 pm CET
ISIN
US45256X1037
Symbol
IBRX
Sector
Industry

ImmunityBio Inc Stock price

$2.78
-2.32 45.49% 1M
-3.76 57.49% 6M
-2.24 44.62% YTD
-2.41 46.44% 1Y
-3.87 58.20% 3Y
-0.96 25.67% 5Y
-31.86 91.97% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
+0.09 3.35%
ISIN
US45256X1037
Symbol
IBRX
Sector
Industry

Key metrics

Market capitalization $2.03b
Enterprise Value $2.92b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 398.26
P/S ratio (TTM) P/S ratio 276.93
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 1,218.71%
Revenue (TTM) Revenue $7.33m
EBIT (operating result TTM) EBIT $-359.29m
Free Cash Flow (TTM) Free Cash Flow $-434.10m
Cash position $130.37m
EPS (TTM) EPS $-0.89
P/E forward negative
P/S forward 84.81
EV/Sales forward 121.97
Short interest 30.80%
Show more

Is ImmunityBio Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

ImmunityBio Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a ImmunityBio Inc forecast:

2x Buy
67%
1x Hold
33%

Analyst Opinions

3 Analysts have issued a ImmunityBio Inc forecast:

Buy
67%
Hold
33%

Financial data from ImmunityBio Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
7.33 7.33
1,209% 1,209%
100%
- Direct Costs 18 18
25% 25%
245%
-11 -11
55% 55%
-145%
- Selling and Administrative Expenses 126 126
55% 55%
1,722%
- Research and Development Expense 204 204
12% 12%
2,789%
-341 -341
1% 1%
-4,656%
- Depreciation and Amortization 18 18
25% 25%
245%
EBIT (Operating Income) EBIT -359 -359
0% 0%
-4,902%
Net Profit -588 -588
28% 28%
-8,019%

In millions USD.

Don't miss a Thing! We will send you all news about ImmunityBio Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ImmunityBio Inc Stock News

Positive
Seeking Alpha
13 days ago
ImmunityBio's recent $100M public offering was necessary to support ANKTIVA's commercialization and pipeline programs, despite the dilution and lower offering price of $3 per share. The company's cash burn rate and financial health remain concerns, but ANKTIVA's impressive performance and future milestones could drive substantial growth and extend the cash runway. IBRX's financial risks persist...
Positive
Seeking Alpha
15 days ago
ImmunityBio's Anktiva shows promise with potential peak revenues of ~$900m annually, but faces significant competition and financial challenges, including a poorly timed $100m fundraising effort. Despite recent setbacks, including a Q3 net loss of $80m and a cash position of $130m, I maintain a "Buy" rating, anticipating positive 2025 catalysts. Anktiva's efficacy in NMIBC and potential in NSCL...
Neutral
GlobeNewsWire
17 days ago
CULVER CITY, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the pricing of its previously announced underwritten public offering of an aggregate of 33,333,334 shares of its common stock at a price to the public of $3.00 per share. ImmunityBio has granted the underwriters a 30-day option to purchase up to an additional...
More ImmunityBio Inc News

Company Profile

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in Culver City, CA.

Head office United States
CEO Richard Adcock
Employees 628
Founded 2014
Website www.immunitybio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today